Anticancer Palliative Care

Product Details:

• Amifostine is used to decrease the risk of kidney problems caused by treatment with a certain anti-cancer drug (cisplatin). It is also used to help prevent a certain side effect (dry mouth) caused by radiation treatment for head and neck cancer. Amifostine is thought to work by preventing certain chemicals from damaging healthy cells. It may also help repair cells damaged by cisplatin or radiation treatment.

• For Reduction of Cumulative Renal Toxicity with Chemotherapy-
• The recommended starting dose of Amifostine for Injection is 910 mg/m2 administered once daily as a 15-minute i.v. infusion, starting 30 minutes prior to chemotherapy.
• The 15-minute infusion is better tolerated than more extended infusions. Further reductions in infusion times for chemotherapy regimens have not been systematically investigated.
• Patients should be adequately hydrated prior to Amifostine for Injection infusion and kept in a supine position during the infusion. Blood pressure should be monitored every 5 minutes during the infusion, and thereafter as clinically indicated.

• The recommended dose of Amifostine for Injection is 200 mg/m2 administered once daily as a 3-minute i.v. infusion, starting 15-30 minutes prior to standard fraction radiation therapy (1.8-2.0 Gy).

Product Details:

• Fluorouracil may be used alone, or in combination for its palliative action in the management of common malignancies particularly cancer of the colon and breast, either as a single agent or in combination with other cytotoxic agents.
• Fluorouracil is indicated in adults.
• Fluorouracil is indicated in the treatment of the following malignancies and disease settings:
• In the treatment of metastatic colorectal cancer
• As adjuvant treatment in colon and rectal cancer
• In the treatment of advanced gastric cancer, pancreatic cancer, oesophageal cancer, metastatic breast cancer,
• As adjuvant treatment in patients with operable primary invasive breast cancer,
• In the treatment of inoperable locally advanced squamous cell carcinoma of the head and neck in previously untreated patients
• In the treatment of locally recurrent or metastatic squamous cell carcinoma of the head and neck

• Fluorouracil injection can be given by intravenous injection or, intravenous or intra-arterial infusion.
• Fluorouracil injection should not be mixed directly, in the same container, with other chemotherapeutic agents or intravenous additives.

• Initial Treatment: This may be in the form of an infusion or an injection, the former usually being preferred because of lesser toxicity.
• Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 500ml of 5% glucose or 0.9% NaCl injection and given by intravenous infusion at a rate of 40 drops per minute over 4 hours. Alternatively the daily dose may be infused over 30 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 15g has been reached.
• Intravenous Injection: 12mg/kg bodyweight, but not more than the recommended 1g daily dose may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course.
• Intra-arterial Infusion: 5/7.5mg/kg may be given by 24 hour continuous intra-arterial infusion.

Product Details:

• Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
• Prevention of nausea and vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.

• Chemotherapy - Induced Nausea & Vomiting

• IV Dose 32mg IV or 150 mcg per kg of body weight.
• Children 150 mcg per kg body weight (6 months to 18 years).
• For prevention of postoperative nausea and vomiting

• IV Dose 4 mg IV over a period of thirty sec. to five min. (Given just before anesthesia).
• Children (1 month to 12 years) 100mcg/kg of weight for children weighing 40 kg or less, or 4 mg for children weighing over 40 kg.